Recital 10, Directive (EU) 2001/83

In forcecited 12×

However, there are reasons of public policy for not conducting repetitive tests on humans or animals without over-riding cause.

The 10 that are cited most themselves, of 12.

  • Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision

    Article 10(1) of Directive 2001/83 — which provides for the possibility of derogating from the requirement laid down in Article 8(3)(i) of that directive to provide the results of pharmaceutical pre-clinical tests and clinical trials for …

    15 Sep 2015 · 62012TJ0472

  • Opinion of Advocate General Wahl delivered on 20 May 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    According to recital 9, obtaining authorisation for a medicinal product which is essentially similar to an authorised product must not place innovative firms at a disadvantage. Recital 10 further states that reasons of public policy …

    20 May 2014 · 62013CC0104

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    Recitals 2, 4, 5 and 10 in the preamble to Directive 2001/83 state: ‘(2) The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. … (4) Trade in medicinal …

    18 Jun 2009 · 62007CJ0527

  • Opinion of Mr Advocate General Bot delivered on 10 July 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DeparDecision

    The latter procedure, I would note, relieves the applicant from the need to provide the results of toxicological and pharmacological tests and clinical trials, if it is shown that the relevant product is ‘essentially similar’ to a …

    10 Jul 2008 · 62006CC0452

  • Opinion of Mr Advocate General Mazák delivered on 26 March 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    Furthermore, Generics considers that the rationale for the abridged procedure is to strike a balance between two sets of competing interests, namely: (i) to facilitate the entry onto the market of generic products, by relieving generic …

    26 Mar 2009 · 62007CC0527

  • Opinion of Advocate General Bobek delivered on 21 December 2016.Decision

    The length of the regulatory data protection period and the possibility to resort to the abridged procedure for marketing authorisation reflects a balance that the EU legislature decided to strike between protection of innovative companies …

    21 Dec 2016 · 62015CC0629

  • Opinion of Advocate General Kokott delivered on 4 October 2018. Staat der Nederlanden v Warner-Lambert Company LLC.Decision

    The rules of EU law on the marketing of medicinal products, in particular Directive 2001/83/EC on medicinal products for human use, [Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community …

    4 Oct 2018 · 62017CC0423

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Article 10(1) of Directive 2001/83 (see paragraph 8 above) seeks to reconcile, on the one hand, the provision of adequate protection for the research and development work undertaken by innovative pharmaceutical companies and, on the other, …

    5 May 2021 · 62018TJ0611

  • Opinion of Advocate General Kokott delivered on 4 June 2020. H. Lundbeck A/S and Lundbeck Ltd v European Commission.Decision

    That latter aspect is of particular importance in the field of medicinal products, where the promotion of research by originator undertakings must be reconciled with the public interest in the marketing of generic medicinal products, which …

    4 Jun 2020 · 62016CC0591

  • Judgment of the Court (Second Chamber) of 23 April 2026. EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS v Agence nationale deDecision

    Recitals 2, 3, 9, 10 and 15 of Directive 2001/83 read as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health However, this objective must be …

    23 Apr 2026 · 62024CJ0118